Reprint

New Insights in the Genetics and Genomics of Adrenocortical Tumors and Pheochromocytomas

Edited by
February 2022
272 pages
  • ISBN978-3-0365-3358-2 (Hardback)
  • ISBN978-3-0365-3357-5 (PDF)

This book is a reprint of the Special Issue New Insights in the Genetics and Genomics of Adrenocortical Tumors and Pheochromocytomas that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This book includes 17 papers published in the Special Issue/Article Collectoin “New Insights in the Genetics and Genomics of adrenocortical tumors and pheochromocytomas” including an editorial, 10 research papers and six review articles. Adrenal tumors represent a hot topic in contemporary endocrine oncology. Significant advancements in the genetics of genomics of these tumors have been made in recent years, and these articles give a useful and comprehensive overview of these issues. Questions regarding molecular pathogenesis, diagnosis (biomarkers) and even treatment are discussed in the papers written by international leaders of the field. Manuscripts are focused on three main topics: i. primary aldosteronism (the most common cause of secondary endocrine hypertension), ii. adrenocortical cancer and iii. pheochromocytoma/paraganglioma, which are the tumors with the highest heritability in humans. The book is edited by Prof. Peter Igaz (Department of Endocrinology, Faculty of Medicine, Semmelweis University).

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
pheochromocytoma; paraganglioma; genetics; non-coding RNA; malignancy; biomarker; treatment; adaptive metabolism; adrenal gland; conn adenoma; fatty acid metabolism; ferroptosis; hyperaldosteronism; metabolic reprogramming; β-oxidation; PPARα; tumor microenvironment; Next Generation Sequencing; pheochromocytoma; paraganglioma; hereditary cancer; endocrine tumor syndrome; KCNJ5 somatic mutation; pulse wave velocity; aldosterone-producing adenoma; adrenalectomy; propensity score matching; arterial stiffness; pheochromocytomas; paragangliomas; mutations; susceptibility genes; driver mutations; hereditary; germline; somatic; environment; variants; tumor suppressor genes; metastatic; treatment; RNAseq; next generation sequencing; adrenocortical carcinoma; in silico analysis; machine learning; bioinformatic clustering; biomarker prediction; aldosterone producing adenoma; ATP2B3; K416-F418delinsN mutation; primary aldosteronism; pheochromocytoma; paraganglioma; PPGL; telomeres; TERT; ATRX; NOP10; prognostic biomarker; ALT; phaeochromocytoma; paraganglioma; cancer; mitochondrial complex II; zebrafish; therapy; drug discovery; redox balance pathway; Vitamin C; mitotane; adrenocortical carcinoma; H295 strains; primary aldosteronism; microRNA; aldosterone; circulating; biomarker; adrenocortical; primary aldosteronism; transcriptomics; epigenetics; metabolomics; pheochromocytoma; paraganglioma; epidemiology; genetic analysis; mortality; surveillance; TP53 R337H; genetic testing; adrenocortical tumor; neonatal screening; surveillance; pheochromocytoma; paraganglioma; genetics; germline; screening; adrenocortical carcinoma; adenoma; adrenal; tissue; microRNA; biomarker; artificial intelligence; neural network; n/a